NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis $2.72 -0.15 (-5.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.60▼$3.0650-Day Range$2.72▼$3.8152-Week Range$2.60▼$85.50Volume133,729 shsAverage Volume70,260 shsMarket Capitalization$2.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends Get Avenue Therapeutics alerts: Email Address Avenue Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.68% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.16Based on 31 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.37 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avenue Therapeutics.Read more about Avenue Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.68% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently increased by 3.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 1.0 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Avenue Therapeutics this week, compared to 8 articles on an average week.MarketBeat FollowsOnly 1 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions.Read more about Avenue Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avenue Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesJuly 25 at 6:14 PM | msn.comInside Look: Roadkill Nights Big Tire and Small Tire Heads-Up Classes on Woodward AvenueJuly 25 at 6:14 PM | msn.comPrepare for lane closure at intersection of Granite Avenue, Grove Avenue in RichmondJuly 27, 2024 | The Oxford Club (Ad)Don't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...July 25 at 6:14 PM | msn.comYbor's 7th Avenue to say goodbye to concrete, reintroduce brick roadJuly 25 at 1:10 PM | seekingalpha.comThird Avenue Real Estate Value Fund Q2 2024 CommentaryJuly 25 at 1:10 PM | msn.comBurlington North Avenue assault ends in arrestJuly 25 at 1:10 PM | msn.com84-year-old driver dies from injuries in crash on Dana AvenueJuly 25 at 1:10 PM | msn.comCourt documents detail investigation into J Avenue stabbing leading to manslaughter chargesJuly 27, 2024 | The Oxford Club (Ad)Don't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...July 25 at 8:08 AM | msn.comCrash with injuries reported on Queen City Avenue in WestwoodJuly 24 at 11:36 PM | msn.comStructure fire reported on Highway Avenue in CovingtonJuly 24 at 7:48 AM | news.yahoo.com1 injured after shooting on Cambridge AvenueJuly 24 at 7:48 AM | msn.comAtlanta police probe deadly shooting along John Wesley Dobbs AvenueJuly 24 at 7:48 AM | msn.comAvenue of the Arts Set to Spend $100M on New Beautification Project Starting in 2025July 24 at 7:48 AM | msn.comEdison may cut down size of new construction along Amboy AvenueJuly 24 at 7:48 AM | msn.comSome lanes of Forest Hill Avenue to close after sewer main collapseJuly 24 at 7:48 AM | msn.comNew owner buys Saint Vincent retail project on Austin's trendy South Congress AvenueJuly 24 at 2:34 AM | msn.comPort Richmond residents call on Philadelphia leadership to fix multiple "dangerous" holes on Aramingo AvenueSee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($7.8817) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-391.98% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book1.42Miscellaneous Outstanding Shares940,000Free Float924,000Market Cap$2.56 million OptionableNot Optionable Beta-0.19 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 57)CEO & Director Comp: $413.2kMr. David Jin (Age 34)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kKey CompetitorsTrevenaNASDAQ:TRVNChemomab TherapeuticsNASDAQ:CMMBKiora PharmaceuticalsNASDAQ:KPRXBriaCell TherapeuticsNASDAQ:BCTXUniverse PharmaceuticalsNYSE:UPCView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions How have ATXI shares performed this year? Avenue Therapeutics' stock was trading at $12.0750 at the beginning of the year. Since then, ATXI stock has decreased by 77.5% and is now trading at $2.72. View the best growth stocks for 2024 here. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($15.40) EPS for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split before market open on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA) and This page (NASDAQ:ATXI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
